Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

2.4K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.4K
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

631
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
631
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

3.6K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.6K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.1K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

609
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
609
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.3K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep-Learning Algorithm Diagnostic Support for Usual Interstitial Pneumonia Pattern Recognition in Fibrotic Interstitial Lung Disease.

Respirology (Carlton, Vic.)·2026
Same author

Likelihood of Usual Interstitial Pneumonia: A Novel Approach to Prognosis for Pulmonary Fibrosis.

Respirology (Carlton, Vic.)·2026
Same author

The role of epigenetic regulation in idiopathic pulmonary fibrosis.

American journal of physiology. Lung cellular and molecular physiology·2025
Same author

Cannabidiol Is Associated with Improved Survival in Pancreatic Cancer and Modulation of Bile Acids and Gut Microbiota.

International journal of molecular sciences·2025
Same author

A Comprehensive Review of Interstitial Lung Abnormalities.

Respirology (Carlton, Vic.)·2025
Same author

Pre-Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients.

Respirology (Carlton, Vic.)·2025

Related Experiment Video

Updated: Jan 27, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.5K

Metabolomics in chronic lung diseases.

Shabarinath Nambiar1, Sze Bong How1,2, Joel Gummer1,2

  • 1Separation Science and Metabolomics Laboratory, Murdoch University, Perth, WA, Australia.

Respirology (Carlton, Vic.)
|March 26, 2019
PubMed
Summary

Metabolomics reveals unique biochemical pathways in chronic lung diseases (CLD) like COPD, IPF, and asthma. This approach analyzes biomolecules in samples to identify new biomarkers for personalized patient care.

Keywords:
asthmachronic obstructive pulmonary diseaseidiopathic pulmonary fibrosislungmetabolomics

More Related Videos

Author Spotlight: Enhancing Diagnostic Strategies and Biomarker Development for Comprehensive Lung Function Analysis
05:56

Author Spotlight: Enhancing Diagnostic Strategies and Biomarker Development for Comprehensive Lung Function Analysis

Published on: August 9, 2024

2.4K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.7K

Related Experiment Videos

Last Updated: Jan 27, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.5K
Author Spotlight: Enhancing Diagnostic Strategies and Biomarker Development for Comprehensive Lung Function Analysis
05:56

Author Spotlight: Enhancing Diagnostic Strategies and Biomarker Development for Comprehensive Lung Function Analysis

Published on: August 9, 2024

2.4K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.7K

Area of Science:

  • Biochemistry
  • Pulmonology
  • Analytical Chemistry

Background:

  • Chronic lung diseases (CLD) pose a significant global health challenge, necessitating personalized patient management.
  • Advancements in metabolomics enable the identification of novel biochemical pathways and disease markers.
  • Analyzing biological samples like bronchoalveolar lavage fluid (BALF) and plasma offers diagnostic potential.

Purpose of the Study:

  • To review the application of metabolomics in studying chronic lung diseases (CLD).
  • To explore the insights gained from metabolomic analytical strategies in understanding CLD biochemistry.
  • To discuss the potential of metabolomics for identifying future clinical biomarkers for CLD.

Main Methods:

  • Utilizing large-scale metabolomic studies to identify biochemical pathways and disease markers.
  • Analyzing samples from different biological compartments, including bronchoalveolar lavage fluid (BALF) and plasma.
  • Employing mass spectrometry (MS) to detect alterations in metabolic pathways, such as sphingolipid metabolism in COPD.

Main Results:

  • Metabolomic studies have identified specific alterations in metabolic pathways associated with CLD.
  • Sphingolipid metabolism has been shown to be altered in patients with chronic obstructive pulmonary disease (COPD).
  • Metabolomics provides valuable insights into the complex biochemistry underlying CLD.

Conclusions:

  • Metabolomics is a promising tool for characterizing chronic lung diseases (CLD).
  • The application of metabolomics aids in dissecting the biochemistry of CLD, including COPD, idiopathic pulmonary fibrosis (IPF), and asthma.
  • Metabolomic findings hold potential for the development of novel clinical biomarkers for improved CLD diagnosis and management.